We've found
35,033
archived clinical trials in
Lung Cancer
We've found
35,033
archived clinical trials in
Lung Cancer
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Updated: 1/1/1970
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Updated: 1/1/1970
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Updated: 1/1/1970
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Updated: 1/1/1970
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Updated: 1/1/1970
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Updated: 1/1/1970
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Updated: 1/1/1970
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Updated: 1/1/1970
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Updated: 1/1/1970
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Updated: 1/1/1970
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Updated: 1/1/1970
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Updated: 1/1/1970
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Updated: 1/1/1970
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Updated: 1/1/1970
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Updated: 1/1/1970
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Erlotinib With or Without IMC-A12 in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
A Randomized Phase II Cross Over Study With a Safety Lead In of the Anti-IGF-1R Monoclonal Antibody IMC-A12 in Combination With Erlotinib Compared With Erlotinib Alone in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Failed At Least One Platinum Containing Chemotherapy Regimen.
Status: Archived
Erlotinib With or Without IMC-A12 in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Updated: 1/1/1970
A Randomized Phase II Cross Over Study With a Safety Lead In of the Anti-IGF-1R Monoclonal Antibody IMC-A12 in Combination With Erlotinib Compared With Erlotinib Alone in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Failed At Least One Platinum Containing Chemotherapy Regimen.
Status: Archived
Updated: 1/1/1970
Erlotinib With or Without IMC-A12 in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
A Randomized Phase II Cross Over Study With a Safety Lead In of the Anti-IGF-1R Monoclonal Antibody IMC-A12 in Combination With Erlotinib Compared With Erlotinib Alone in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Failed At Least One Platinum Containing Chemotherapy Regimen.
Status: Archived
Erlotinib With or Without IMC-A12 in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Updated: 1/1/1970
A Randomized Phase II Cross Over Study With a Safety Lead In of the Anti-IGF-1R Monoclonal Antibody IMC-A12 in Combination With Erlotinib Compared With Erlotinib Alone in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Failed At Least One Platinum Containing Chemotherapy Regimen.
Status: Archived
Updated: 1/1/1970
A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)
A Phase I Study of Dasatinib With Concurrent Chemoradiation for Stage III NSCLC Principal Investigator: Howard Safran, MD.
Status: Archived
A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)
Updated: 1/1/1970
A Phase I Study of Dasatinib With Concurrent Chemoradiation for Stage III NSCLC Principal Investigator: Howard Safran, MD.
Status: Archived
Updated: 1/1/1970
Dasatinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery
A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors
Status: Archived
Dasatinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery
Updated: 1/1/1970
A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Gemcitabine and Cisplatin in Treating Patients With Stage I Non-Small Cell Lung Cancer That Was Removed by Surgery
Updated: 1/1/1970
Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970